153 related articles for article (PubMed ID: 18469443)
1. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
Chalasani P; Kurtin S; Dragovich T
JOP; 2008 May; 9(3):305-8. PubMed ID: 18469443
[TBL] [Abstract][Full Text] [Related]
2. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA).
Klapdor R; Bahlo M; Babinsky A
Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083
[TBL] [Abstract][Full Text] [Related]
3. [A case of pancreatic cancer surviving for 7 years 11 months following intra-arterial and portal infusion chemotherapy].
Kenmotsu M; Endo T; Ishii H; Ichikawa J; Tsunemitsu K
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1983-5. PubMed ID: 7487131
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
James E; Waldron-Lynch MG; Saif MW
Anticancer Drugs; 2009 Aug; 20(7):634-8. PubMed ID: 19433978
[TBL] [Abstract][Full Text] [Related]
5. Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer.
Klapdor R; Bahlo M; Babinsky A; Brenzinger ML
Anticancer Res; 2007; 27(4A):1789-94. PubMed ID: 17649774
[TBL] [Abstract][Full Text] [Related]
6. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group.
Cho JH; Bang S; Park SW; Chung JB; Song SY
Pancreas; 2008 May; 36(4):337-40. PubMed ID: 18437078
[TBL] [Abstract][Full Text] [Related]
7. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
[TBL] [Abstract][Full Text] [Related]
8. A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature.
Ghataorhe P; Kurian AW; Pickart A; Trapane P; Norton JA; Kingham K; Ford JM
Cancer Genet Cytogenet; 2007 Dec; 179(2):89-92. PubMed ID: 18036394
[TBL] [Abstract][Full Text] [Related]
9. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
10. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
Sonnenblick A; Kadouri L; Appelbaum L; Peretz T; Sagi M; Goldberg Y; Hubert A
Cancer Biol Ther; 2011 Aug; 12(3):165-8. PubMed ID: 21613821
[TBL] [Abstract][Full Text] [Related]
11. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
13. [Isolated hypoxic perfusion with mitomycin C confers no benefit for patients with advanced pancreatic carcinoma].
Petrowsky H; Heinrich S; Staib-Sebler E; Gog C; Janshon G; Lorenz M
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1351-3. PubMed ID: 9931879
[TBL] [Abstract][Full Text] [Related]
14. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Lowery M; Shah MA; Smyth E; Epstein A; Segal A; Rosengarten O; Isacson R; Drukker L; Keinan A; Rachkiman M; Reissman P; Gabizon A; Kelsen D; O'Reilly EM
J Gastrointest Cancer; 2011 Sep; 42(3):160-4. PubMed ID: 20711688
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Li M; Zhang J; Wang D; Zhong B; Tucker S; Lu C; Cheng J; Cao C; Xu J; Xu J; Pan H
Anticancer Drugs; 2009 Nov; 20(10):941-5. PubMed ID: 19745719
[TBL] [Abstract][Full Text] [Related]
16. Does OPTIMOX strategy ("stop-and-go" approach) also work in treatment of pancreatic cancer with oxaliplatin-based regimens?
Saif MW
JOP; 2008 Sep; 9(5):658-63. PubMed ID: 18762700
[TBL] [Abstract][Full Text] [Related]
17. Perspectives in chemotherapy of pancreatic cancer.
Klapdor R
Eur J Surg Oncol; 1991 Apr; 17(2):153-66. PubMed ID: 1707835
[No Abstract] [Full Text] [Related]
18. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
20. [Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response].
Lamy R; Conroy T; Brunaud L; Bresler L
Gastroenterol Clin Biol; 2001 Oct; 25(10):912-3. PubMed ID: 11852397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
